Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma
June 18, 2024 08:00 ET
|
Erasca, Inc.
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to date Favorable mOS and mPFS...
Erasca to Present at Upcoming Investor Conferences in June
May 29, 2024 08:00 ET
|
Erasca, Inc.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
May 21, 2024 16:05 ET
|
Erasca, Inc.
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
May 16, 2024 20:02 ET
|
Erasca, Inc.
Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce...
Erasca Announces Pricing of Underwritten Offering of Common Stock
May 16, 2024 20:00 ET
|
Erasca, Inc.
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Reports First Quarter 2024 Business Updates and Financial Results
May 08, 2024 16:01 ET
|
Erasca, Inc.
Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and...
Erasca to Present at the Bank of America Health Care Conference
May 07, 2024 08:00 ET
|
Erasca, Inc.
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
April 24, 2024 16:05 ET
|
Erasca, Inc.
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature...
Erasca Announces $45 Million Oversubscribed Private Placement Financing
March 27, 2024 20:30 ET
|
Erasca, Inc.
SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS) (“Erasca”), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing...
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
March 27, 2024 16:01 ET
|
Erasca, Inc.
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib...